Literature DB >> 11599328

Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma.

A L Kozyrskyj1, C A Mustard, M S Cheang, F E Simons.   

Abstract

BACKGROUND: Drug benefit policies are an important determinant of a population's use of prescription drugs. This study was undertaken to determine whether a change in a provincial drug benefit policy, from a fixed deductible and copayment system to an income-based deductible system, resulted in changes in receipt of prescriptions for inhaled corticosteroids by Manitoba children with asthma.
METHODS: Using Manitoba's health care administrative databases, we identified a population-based cohort of 10,703 school-aged children who met our case definition for asthma treatment before and after the province's drug benefit policy was changed in April 1996. The effects of the program change on the probability of receiving a prescription for an inhaled corticosteroid and on the mean number of inhaled corticosteroid doses dispensed were compared between a group of children insured under other drug programs (the comparison group) and 2 groups of children insured under the deductible program: those living in low-income neighbourhoods and those living in higher-income neighbourhoods. All analyses were adjusted for a measure of asthma severity.
RESULTS: For higher-income children with severe asthma who were covered by the deductible program, the probability of receiving an inhaled corticosteroid prescription and the mean annual number of inhaled corticosteroid doses declined after the change to the drug policy. A trend toward a decrease in receipt of prescriptions was also observed for low-income children, but receipt of prescriptions was unaltered in the comparison group. Before the policy change, among children with severe asthma, the mean annual number of inhaled corticosteroid doses was lowest for low-income children, and this pattern persisted after the change. Among children with mild to moderate asthma, those covered by the deductible program (both low income and higher income) were less likely to receive prescriptions for inhaled corticosteroids than those in the comparison group, and this difference was statistically significant for the higher-income children.
INTERPRETATION: The change to an income-based drug benefit policy was associated with a decrease in the use of inhaled corticosteroids by higher-income children with severe asthma and did not improve use of these drugs by low-income children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599328      PMCID: PMC81497     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  32 in total

1.  The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.

Authors:  B L Harris; A Stergachis; L D Ried
Journal:  Med Care       Date:  1990-10       Impact factor: 2.983

2.  Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment.

Authors:  S B Soumerai; D Ross-Degnan; S Gortmaker; J Avorn
Journal:  JAMA       Date:  1990-02-09       Impact factor: 56.272

3.  Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994.

Authors:  D Gaist; J Hallas; N C Hansen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1996-04       Impact factor: 4.335

Review 4.  Severity of childhood asthma by socioeconomic status.

Authors:  A Mielck; P Reitmeir; M Wjst
Journal:  Int J Epidemiol       Date:  1996-04       Impact factor: 7.196

5.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

Authors:  R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

Review 6.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

7.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

Authors:  S B Soumerai; J Avorn; D Ross-Degnan; S Gortmaker
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

8.  Respiratory infections and the autumn increase in asthma morbidity.

Authors:  R E Dales; I Schweitzer; J H Toogood; M Drouin; W Yang; J Dolovich; J Boulet
Journal:  Eur Respir J       Date:  1996-01       Impact factor: 16.671

9.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

10.  Direct and indirect costs of asthma in Canada, 1990.

Authors:  M D Krahn; C Berka; P Langlois; A S Detsky
Journal:  CMAJ       Date:  1996-03-15       Impact factor: 8.262

View more
  18 in total

1.  Prescription to over-the-counter deregulation in Canada: are we ready for it, or do we need to be?

Authors:  Larry D Lynd; Jeffrey Taylor; Roy Dobson; Donald J Willison
Journal:  CMAJ       Date:  2005-09-12       Impact factor: 8.262

2.  Childhood asthma surveillance using administrative data: consistency between medical billing and hospital discharge diagnoses.

Authors:  France Labrèche; Tom Kosatsky; Raymond Przybysz
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

3.  Health insurance, access to prescription medicines and health outcomes in children.

Authors:  Wendy J Ungar; Rinat Ariely
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2005-04       Impact factor: 2.217

4.  Impact of income-based deductibles on drug use and health care utilization among older adults.

Authors:  Michael R Law; Lucy Cheng; Heather Worthington; Muhammad Mamdani; Kimberlyn M McGrail; Fiona K I Chan; Sumit R Majumdar
Journal:  CMAJ       Date:  2017-05-15       Impact factor: 8.262

5.  Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma.

Authors:  Wendy J Ungar; J Michael Paterson; Tara Gomes; Peter Bikangaga; Milton Gold; Teresa To; Anita L Kozyrskyj
Journal:  Ann Allergy Asthma Immunol       Date:  2010-11-20       Impact factor: 6.347

6.  Impact of Copayment Changes on Children's Albuterol Inhaler Use and Costs after the Clean Air Act Chlorofluorocarbon Ban.

Authors:  Alison A Galbraith; Vicki Fung; Lingling Li; Melissa G Butler; James D Nordin; John Hsu; David Smith; William M Vollmer; Tracy A Lieu; Stephen B Soumerai; Ann Chen Wu
Journal:  Health Serv Res       Date:  2016-11-20       Impact factor: 3.402

7.  Can increases in CHIP copayments reduce program expenditures on prescription drugs?

Authors:  Bisakha Sen; Justin Blackburn; Michael Morrisey; David Becker; Meredith Kilgore; Cathy Caldwell; Nir Menachemi
Journal:  Medicare Medicaid Res Rev       Date:  2014-05-20

8.  Socioeconomic factors and asthma control in children.

Authors:  Shannon F Cope; Wendy J Ungar; Richard H Glazier
Journal:  Pediatr Pulmonol       Date:  2008-08

9.  Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.

Authors:  Colin R Dormuth; Peter Neumann; Malcolm Maclure; Robert J Glynn; Sebastian Schneeweiss
Journal:  Med Care       Date:  2009-05       Impact factor: 2.983

10.  Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.

Authors:  Colin R Dormuth; Malcolm Maclure; Robert J Glynn; Peter Neumann; Alan M Brookhart; Sebastian Schneeweiss
Journal:  Clin Ther       Date:  2008       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.